News
Novo Nordisk beats on Q1 earnings, cuts 2025 outlook
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.
COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for ...
Novo Nordisk (NVO, NOVO-B.CO) said first-quarter sales of its first-to-market weight-loss drug Wegovy were 17.36bn Danish ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...
Semaglutide is marketed under the brand names Wegovy ® (once-weekly semaglutide 2.4 mg injection), Ozempic ® (once-weekly ...
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback